Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Short term Debt (2023 - 2025)

Spyre Therapeutics' Short term Debt history spans 3 years, with the latest figure at $22.8 million for Q4 2025.

  • For Q4 2025, Short term Debt fell 9.01% year-over-year to $22.8 million; the TTM value through Dec 2025 reached $22.8 million, down 9.01%, while the annual FY2025 figure was $22.8 million, 9.01% down from the prior year.
  • Short term Debt reached $22.8 million in Q4 2025 per SYRE's latest filing, up from $11.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $164.4 million in Q2 2023 to a low of $1.4 million in Q4 2023.
  • Average Short term Debt over 3 years is $33.2 million, with a median of $22.8 million recorded in 2025.
  • Peak YoY movement for Short term Debt: crashed 98.39% in 2024, then surged 2168.94% in 2025.
  • A 3-year view of Short term Debt shows it stood at $1.4 million in 2023, then surged by 1704.32% to $25.1 million in 2024, then decreased by 9.01% to $22.8 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Short term Debt are $22.8 million (Q4 2025), $11.0 million (Q3 2025), and $59.9 million (Q2 2025).